According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
NTRA has been the subject of a number of other research reports. Canaccord Genuity restated a “buy” rating and issued a $25.00 target price on shares of Natera in a research note on Monday, March 11th. BidaskClub upgraded Natera from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 20th. Finally, ValuEngine upgraded Natera from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $28.00.
Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, March 12th. The medical research company reported ($0.51) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.51). The company had revenue of $67.00 million during the quarter, compared to analysts’ expectations of $62.87 million. Natera had a negative return on equity of 790.13% and a negative net margin of 49.72%. As a group, research analysts expect that Natera will post -2.24 earnings per share for the current fiscal year.
In related news, insider Jonathan Sheena sold 23,356 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $20.51, for a total transaction of $479,031.56. Following the completion of the transaction, the insider now owns 294,758 shares of the company’s stock, valued at approximately $6,045,486.58. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Matthew Rabinowitz sold 5,672 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $16.00, for a total value of $90,752.00. Following the transaction, the insider now directly owns 1,288,853 shares of the company’s stock, valued at approximately $20,621,648. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 351,313 shares of company stock valued at $7,132,873. 13.18% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of NTRA. First Manhattan Co. lifted its position in shares of Natera by 98.8% in the first quarter. First Manhattan Co. now owns 1,027,242 shares of the medical research company’s stock valued at $21,181,000 after acquiring an additional 510,509 shares in the last quarter. Capital Impact Advisors LLC lifted its position in shares of Natera by 25.5% in the fourth quarter. Capital Impact Advisors LLC now owns 102,617 shares of the medical research company’s stock worth $1,338,000 after buying an additional 20,834 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Natera by 6.1% in the fourth quarter. Geode Capital Management LLC now owns 463,029 shares of the medical research company’s stock worth $6,463,000 after buying an additional 26,771 shares in the last quarter. FMR LLC lifted its position in shares of Natera by 57.0% in the fourth quarter. FMR LLC now owns 3,908,921 shares of the medical research company’s stock worth $54,568,000 after buying an additional 1,419,390 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its position in shares of Natera by 5.5% in the fourth quarter. Macquarie Group Ltd. now owns 2,095,447 shares of the medical research company’s stock worth $29,252,000 after buying an additional 109,869 shares in the last quarter. 87.76% of the stock is owned by institutional investors.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: What are catch-up contributions?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.